Schonfeld Strategic Advisors LLC Sells 173,774 Shares of enGene Holdings Inc. (NASDAQ:ENGN)

Schonfeld Strategic Advisors LLC lessened its position in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 56.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 132,260 shares of the company's stock after selling 173,774 shares during the quarter. Schonfeld Strategic Advisors LLC owned 0.30% of enGene worth $880,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ENGN. Vontobel Holding Ltd. purchased a new position in shares of enGene during the fourth quarter worth approximately $69,000. Franklin Resources Inc. grew its holdings in shares of enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after purchasing an additional 389,918 shares during the last quarter. Finally, Blue Owl Capital Holdings LP raised its position in enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company's stock worth $21,014,000 after purchasing an additional 101,006 shares during the period. Hedge funds and other institutional investors own 64.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ENGN. UBS Group cut enGene from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $34.00 to $7.00 in a research note on Friday, February 14th. Piper Sandler assumed coverage on shares of enGene in a research report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target for the company. JMP Securities restated a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a research report on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of enGene in a research note on Tuesday, March 11th. Finally, Morgan Stanley dropped their price target on enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $23.29.

enGene Stock Down 12.7 %

Shares of NASDAQ:ENGN traded down $0.43 during trading on Friday, reaching $2.96. 32,954 shares of the stock traded hands, compared to its average volume of 127,488. The stock has a market cap of $150.89 million, a P/E ratio of -5.10 and a beta of -0.36. enGene Holdings Inc. has a 52-week low of $2.94 and a 52-week high of $14.37. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The stock has a 50-day moving average of $4.40 and a two-hundred day moving average of $6.28.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.